Company: DNLI
Filing Date: 2025-04-17
Form Type: DEF 14A
Source: 0001714899-25-000087
Chunk: 64

Company: Denali Therapeutics Inc.
Filing Date: 2025-04-17
Form: DEF 14A
Chunk 64
---
|                           |     | TOTAL                                                                 |     | $                 | — |   |     | $                                             | 3,249,327 |           |     | $                         |   675,241 |         |
| Carole Ho, M.D.           |     | Base Salary                                                           |     | $                 | — |   |     | $                                             |   536,000 |           |     | $                         |   402,000 |         |
|                           |     | Target Bonus                                                          |     |                   |   | — |     |                                               |           |   241,200 |     |                           |           | 241,200 |
|                           |     | Welfare(1)                                                            |     |                   |   | — |     |                                               |           |    53,829 |     |                           |           |  40,372 |
|                           |     | Restricted Stock Units(2)                                             |     |                   |   | — |     |                                               |           | 2,421,348 |     |                           |           |       — |
|                           |     | Stock Options(3)                                                      |     |                   |   | — |     |                                               |           |     8,058 |     |                           |           |       — |
|                           |     | TOTAL                                                                 |     | $                 | — |   |     | $                                             | 3,260,435 |           |     | $                         |   683,572 |         |

<div align='center'>-47-</div>

(1) Represents the lump sum aggregate premium payments, including the two-percent administrative charge, that would be required to be paid to or on behalf of the NEO to provide continued health insurance coverage under COBRA (based on the executive's health insurance coverage as of December 31, 2024) for 9 (12 for Dr. Watts) months for termination without cause and 12 (24 for Dr. Watts) months for a qualified termination that occurs within 12 months of the consummation of a change in control.

(2) Assuming assumption of the outstanding equity awards by a buyer, upon the consummation of a change in control and a qualifying termination with the change in control period, all time-based RSU awards accelerate vesting. The value of accelerated RSUs is calculated by multiplying the numbers of shares subject to acceleration by the closing price of our common stock on December 31, 2024, which was $20.38.

(3